NATCO PHARMA LIMITED

NATCO PHARMA LIMITED

‍

Samiksha: Quarterly Earnings Deep-Dive Analysis Q2 FY2026 (July–September 2025)

Extracting Alpha out of Quarterly Results

‍

EXECUTIVE SUMMARY DASHBOARD

Key Metrics

• Execution Score (0–100): 68 / 100
• Management Credibility Score: 72 / 100
• Quarter Surprise Factor: MISS on Profitability; MEET on Revenue

Financial Variance (YoY)

• Revenue Variance: -0.6% YoY (₹1,363 Cr vs ₹1,371 Cr) → Flat
• EBITDA Variance: -21.8% YoY (₹679 Cr vs ₹868 Cr) → Significant Miss
• PAT Variance: -23.5% YoY (₹518 Cr vs ₹677 Cr) → Major Miss

Investment Thesis Impact

NEUTRAL — Strategic initiatives on track, but near-term profitability under pressure.

Key Takeaway

Natco delivered on strategic execution (Adcock Ingram acquisition completed; CHS demerger approved) but sacrificed short-term profitability for long-term positioning through elevated R&D investments and one-time costs.

Quarter Grade: B- (Good strategic execution; concerning profit decline)

1. STRATEGIC EXECUTION TRACKER

Promise vs. Performance Matrix

Adcock Ingram Acquisition

• Original Timeline: Announced July 2025; complete by Q3 FY26
• Current Status: ✅ COMPLETED Nov 11, 2025 — Acquired 35.75% stake for $226M; delisted from JSE
• Variance: Ahead of schedule by ~1 month
• Credibility Score: ⭐⭐⭐⭐⭐ (100 / 100)

Crop Health Sciences Demerger

• Original Timeline: Evaluation announced Sept 2025; finalization by Q4 FY26
• Current Status: ✅ ON TRACK — Board approved in-principle; management evaluating optimal structure
• Variance: As per timeline; Natco to retain minority stake for R&D support
• Credibility Score: ⭐⭐⭐⭐ (90 / 100)

Base Business Growth (10–15% CAGR)

• Guidance: Q1 FY26 guidance: 10–15% annual base growth
• Current Status: ⚠️ UNDERPERFORMED — Revenue flat YoY at -0.6%; QoQ +2.5%
• Explanation: Revlimid pricing pressure offset other segment growth
• Credibility Score: ⭐⭐⭐ (60 / 100)

FY26 PAT Guidance (₹1,275–1,300 Cr)

• Guidance: Reiterated Q1 FY26; ~30% YoY decline expected
• Current Status: ⚠️ AT RISK — H1 FY26 PAT at ₹998 Cr; requires ₹277–302 Cr in H2
• Explanation: H1 tracking below guidance; Q3/Q4 need strong recovery
• Credibility Score: ⭐⭐ (50 / 100)

R&D Investment for Future Pipeline

• Guidance: Elevated R&D through Sept; decline from Dec onwards
• Current Status: ✅ DELIVERED — Substantial R&D on bioequivalence, oncology, peptides
• Explanation: One-time spike as guided; positions for 20+ Para IV FTF filings
• Credibility Score: ⭐⭐⭐⭐ (85 / 100)

Crop Health Sciences Breakeven

• Guidance: Reach breakeven by H2 FY26
• Current Status: ✅ ON TRACK — Q2 revenue ₹52.4 Cr vs ₹14.1 Cr YoY; losses narrowing
• Explanation: 271% YoY growth; new fungicide launches improving margins
• Credibility Score: ⭐⭐⭐⭐ (85 / 100)

Revlimid Market Share (33% by Jan 2026)

• Guidance: Scale to 33% market share by exclusivity end
• Current Status: ❓ NOT DISCLOSED — Export formulations declined to ₹1,147 Cr YoY
• Explanation: Pricing erosion accelerating; Jan 2026 full generic entry looming
• Credibility Score: ⭐⭐⭐ (65 / 100)

MANAGEMENT CREDIBILITY SCORE: 72 / 100

Historical Guidance Accuracy (Last 8 Quarters)

• Revenue Growth: 6 / 8 quarters met (75%)
• Margin Expansion: 4 / 8 quarters met (50%)
• Strategic Milestones: 7 / 8 met (87.5%)
• Capex Deployment: 7 / 8 met (87.5%)

Assessment:
Management shows strong credibility on strategic initiatives (M&A, demergers, pipeline building) but struggles with profit forecasting in a volatile generic pricing environment. Revlimid erosion timing was communicated accurately, but the speed of pricing pressure appears underestimated.

RESOURCE ALLOCATION EFFICIENCY

Capital Deployment (H1 FY26)

• Adcock Ingram Acquisition: $226M (~₹1,900 Cr) — Africa entry gateway
• R&D Investments: Elevated spend on bioequivalence, oncology, peptides, oligonucleotides
• Capex: ₹180 Cr — maintenance-focused
• Working Capital: Total assets increased to ₹10,430 Cr from ₹8,631 Cr

Human Resources

• One-time employee bonus paid in Q2 (₹50–60 Cr estimated impact)

Strategic Pivot

Clear shift from “Revlimid dependency” to “geographic diversification + next-gen pipeline.”
Adcock provides ~30% South African market access; CHS demerger enables focused pharma management.

Efficiency Rating: 7.5 / 10

2. EARNINGS QUALITY & SUSTAINABILITY ASSESSMENT

Core Earnings Reconciliation

Revenue from Operations

• Q2 FY26: ₹1,363 Cr
• YoY: -0.6%
• QoQ: +2.5%
• Adjustments: Nil
• Core Revenue: ₹1,363 Cr

Other Operating Income

• Q2 FY26: ₹104.3 Cr
• Adjustment: (-₹30 Cr) non-recurring
• Core OI: ₹74 Cr

Total Expenses

• Q2 FY26: ₹849.3 Cr
• Adjustment: (-₹80 Cr) one-time R&D + bonus
• Core Expenses: ₹769 Cr

EBITDA

• Reported: ₹679.2 Cr
• Adjustment: +₹50 Cr
• Core EBITDA: ₹729 Cr

Net Profit (PAT)

• Reported: ₹517.9 Cr
• Adjustment: +₹60 Cr
• Core PAT: ₹578 Cr

Adjusted Core PAT decline: 14.5% YoY vs reported 23.5%.

One-Time Items Identified

1. Elevated R&D expenses: ₹60–70 Cr
2. Employee bonus: ₹50–60 Cr
3. Business provisions: ₹10–15 Cr
4. Excess other income: ₹30 Cr

Earnings Quality Score: 75 / 100

CASH CONVERSION ANALYSIS

Key Metrics

• Operating Cash Flow (H1 FY26): ₹1,191 Cr
• Free Cash Flow: ₹1,011 Cr
• OCF / PAT Ratio: 1.19x
• Capex Intensity: 13% of revenue

Cash Position

• Net Cash (Sept 30, 2025): ₹3,903 Cr

Quality of Earnings Score: 85 / 100

MARGIN SUSTAINABILITY

Margin Evolution

• Q2 FY25 EBITDA Margin: 60.5%
• Q1 FY26 EBITDA Margin: 45.5%
• Q2 FY26 EBITDA Margin: 46.4%
• Core Q2 FY26 EBITDA Margin: 50.8%

Margin Quality Score

70 / 100

3. FORWARD-LOOKING STRATEGIC INTELLIGENCE

Management Tone Analysis

• Sentiment Score: 6.5 / 10
• Tone: Cautiously optimistic; strong emphasis on pipeline and Africa strategy

Strategic Priority Shift

• From maximizing Revlimid tail → minimizing dependency
• Organic growth → inorganic expansion (Adcock)
• Experimental CHS → value-unlocking demerger
• Maintain R&D → front-load R&D aggressively

9. INVESTMENT RECOMMENDATION

PRIMARY RECOMMENDATION: BUY

• Target Price: ₹1,750
• Current Price: ₹826
• Upside Potential: 112% over 24 months
• Investment Horizon: 18–24 months
• Risk Rating: MEDIUM–HIGH

FINAL INVESTMENT THESIS SUMMARY

Natco Pharma offers an asymmetric risk–reward setup driven by deep valuation discount, strategic transformation (Adcock acquisition, CHS demerger), and a rich Para IV pipeline. While near-term volatility around Revlimid is unavoidable, medium-term execution could unlock substantial shareholder value.

‍

‍

Compliance & Disclosures

© 2025 Oorjita FinAI Services. All rights reserved.

Oorjita.ai is not operated by a broker, dealer, or a registered investment adviser. Under no circumstances does any information published on www.oorjita.ai constitute a recommendation to buy or sell any security.

The information provided on this website and in its related newsletters is for informational purposes only and is not intended to be, nor should it be construed as, investment advice or investment recommendations.

While we strive for accuracy, the information on this site is provided without any guarantees as to completeness, accuracy, or timeliness.

In no event shall Oorjita FinAI Services be liable to any member, guest, or third party for any damages of any kind arising from the use of, or inability to use, this website or any content published herein — including, without limitation, investment losses, lost profits, lost opportunities, or any special, incidental, indirect, consequential, or punitive damages.

Past performance is not indicative of future results.

‍

‍